source
- Thiel-backed Lindus Therapeutics sells CRO division and shifts focus to acquiring drug assetsLindus Therapeutics, a transatlantic startup backed by Peter Thiel, announced the sale of its contract research organization (CRO) arm. The company, previously positioning itself as an “anti‑CRO,”…
- Akeso and Summit report ivonescimab meets overall survival endpoint in Phase 3 lung cancer trialAkeso and its partner Summit said the Phase 3 trial of ivonescimab, a PD-1xVEGF bispecific antibody, has met its overall survival endpoint in a selected group of lung cancer patients. The announcem…